PFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• PFA Pension Forsikringsaktieselskab bought a new stake of 92,850 shares in Regeneron, valued at about $71.86 million, representing roughly 0.09% ownership at quarter-end.
• Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and unveiled a $3 billion share buyback, but shares fell; analysts remain mostly constructive with a consensus target of about $826.59 and notable upward targets (e.g., JPMorgan $950, Guggenheim $995).
• Insiders have been net sellers recently: SVP Jason Pitofsky sold 2,036 shares (~$1.585M) and insiders sold 3,774 shares worth ~$2.94M over the last 90 days, with corporate insiders owning 7.02% of the stock.

PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 92,850 shares of the biopharmaceutical company's stock, valued at approximately $71,861,000. PFA Pension Forsikringsaktieselskab owned about 0.09% of Regeneron Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. WPG Advisers LLC raised its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares during the period. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $27,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. Caitlin John LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Finally, FNY Investment Advisers LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $38,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,774 shares of company stock worth $2,942,738. Corporate insiders own 7.02% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on REGN. Royal Bank Of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a "sector perform" rating on the stock in a research note on Thursday. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research note on Thursday. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a report on Thursday. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a research note on Monday, February 2nd. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $826.59.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Regeneron Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ REGN opened at $701.42 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The business has a 50-day simple moving average of $756.81 and a two-hundred day simple moving average of $736.41. The company has a quick ratio of 3.39, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a market cap of $74.15 billion, a P/E ratio of 17.09, a P/E/G ratio of 1.61 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the firm earned $8.22 EPS. The business's quarterly revenue was up 19.0% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.